The pharmaceutical industry continues to transform under the impetus of artificial intelligence (AI), which is emerging as a major catalyst for innovation. Recent collaborations between Eli Lilly and BigHat Biosciences illustrate this dynamic, with AI at the heart of antibody discovery. Meanwhile, Sanofi and Takeda are continuing their integration of AI into research and development (R&D), strengthening their strategic positioning in the global market. This evolution is supported by significant investments and technological advances that promise to reduce the time-to-market for new drugs.
Débloquez l'Analyse Complète
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.
